Eugene, OR, United States of America

John Joseph Naleway

USPTO Granted Patents = 23 

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 544(Granted Patents)


Company Filing History:


Years Active: 1993-2020

Loading Chart...
23 patents (USPTO):Explore Patents

Title: Innovations in Targeted Therapeutics: The Contributions of John Joseph Naleway

Introduction

John Joseph Naleway, based in Eugene, OR, has made significant contributions to the field of therapeutics, specifically through his innovative patents. With a remarkable portfolio of 23 patents, his work primarily focuses on the development of targeted peptide conjugates for therapeutic applications.

Latest Patents

Naleway's latest inventions include "Targeted peptide conjugates" and "Intracellular organelle peptide targeted enzyme substrates." The targeted peptide conjugates invention offers methods for preparing therapeutic compounds aimed at specific subcellular target areas, like lysosomes and mitochondria. These compounds are designed to modify enzyme activity within targeted cellular organelles, paving the way for more effective disease treatment.

The invention concerning intracellular organelle peptide targeted enzyme substrates relates to substrates that enable visualization of intracellular organelles through enzyme activity. These compounds are particularly noteworthy because they produce high fluorescence signals under lower pH conditions typical of certain organelles, allowing for monitoring of enzyme activity within cells at minimal concentrations.

Career Highlights

Throughout his career, Naleway has worked with notable companies, including Marker Gene Technologies, Inc. and Molecular Probes, Inc., where he honed his skills in peptide technology and therapeutic development. His innovative approaches have positioned him as a prominent figure in the scientific community.

Collaborations

Naleway's collaborative work has been enriched by partnerships with esteemed colleagues like Richard P. Haugland and Daniel J. Coleman. Together, they have explored the intricacies of enzyme activity and targeted therapies, contributing valuable insights to the field.

Conclusion

John Joseph Naleway's dedication to innovation in therapeutic development through targeted peptides highlights the importance of specific organelle targeting in the treatment of diseases. His contributions have opened new avenues in biological research and pharmaceutical applications, showing the potential of targeted therapies in improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…